Abstract
Abstract
Recombinant vectored vaccines offer trailer-made immunization strategies and are economical, quick to engineer and demand less laboratory infrastructures. Here we describe a detailed protocol for genetic manipulation of vesicular stomatitis virus (VSV) vector system encoding the antigenomic sense RNA of VSV by replacing VSV glycoprotein (VSV-G) with modular rabies virus glycoprotein (RV-G) gene. The production of replication competent recombinant VSV (rVSV) involves the transient transfection of BHK-21 cells with pVSV-expressing RV-G backbone along with transcriptional initiating helper plasmids under the control of T7 polymerase. In addition, we provide comprehensive guidelines on functional, molecular, and structural characterization of the recombinant rVSV-based rabies vaccine.
Funder
Biotechnology and Biological Sciences Research Council
Newton Fund
Publisher
Research Square Platform LLC
Reference20 articles.
1. Development and applications of VSV vectors based on cell tropism;Tani H;Front Microbiol,2012
2. Adding Genes to the RNA Genome of Vesicular Stomatitis Virus: Positional Effects on Stability of Expression;Wertz GW;J Virol,2002
3. Understanding and altering cell tropism of vesicular stomatitis virus;Hastie E;Virus Res,2013
4. Tell JG, Coller BG, Dubey SA, Jenal U, Lapps W, Wang L, Wolf J (2020) Environmental Risk Assessment for rVSV ∆ G-ZEBOV-GP. a Genetically Modified Live Vaccine for Ebola Virus Disease
5. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge;Yahalom-Ronen Y;Nat Commun,2020